

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 11/17/1942  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 01/01/2017 12:34

**Acid-Fast Bacillus (AFB) Identification with Reflex to Susceptibility**

ARUP test code 0060997

Collected: 8/27/2019 13:59 MT  
Started: 9/19/2019 15:02 MT

Source: **Tissue**

Body Site: **Right Arm**

Free Text Sources: **Tissue**

**Final Report**

Mycobacterium intracellulare  
Identification by DNA sequencing.  
Test developed and characteristics determined by  
ARUP Laboratories. See Compliance Statement B:  
aruplab.com/CS

**Susceptibility Results**

**Organism: Mycobacterium intracellulare**

<b>Amikacin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>4</b>
<b>Clarithromycin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>0.25</b>
<b>Linezolid</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>8</b>
<b>Moxifloxacin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>0.5</b>

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate,  
SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**Interpretive Information**

Interpretation: **SEE NOTE**

For Mycobacterium avium-intracellulare complex, CLSI recommends testing and reporting clarithromycin, moxifloxacin, amikacin and linezolid. The reported amikacin interpretation is for IV; if using amikacin (liposomal, inhaled), the MIC interpretive breakpoints are <=64 ug/mL Susceptible, >=128 ug/mL Resistant. The in vivo effectiveness of Moxifloxacin and Linezolid for MAC disease is unproven. Ethambutol, rifampin and rifabutin MIC results are not reported because MIC values are not predictive of clinical responses and may be misleading.

Susceptibility performed by a non-standardized methodology. Interpret results in conjunction with clinical presentation. Test developed and characteristics determined by ARUP Laboratories. See compliance Statement B: aruplab.com/CS.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Acid-Fast Bacillus (AFB) Identification with Reflex to Susceptibility	19-262-401916	8/27/2019 1:59:00 PM	9/19/2019 1:57:20 PM	10/3/2019 11:08:11 AM

END OF CHART

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 19-262-401916  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 2/16/2021 7:29:52 AM  
4848